AD-5423 Dainippon Pharmaceutical Co Ltd

IDrugs

Volumn 1, Issue 7, 1998, Pages 813-817

  Heading, Christine E ^a  

^a NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33748059229     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. AD-5423. Antipsychotic Oka M, Hino K DRUGS FUTURE 1992 17 1 9-11
2. Pharmacological profile of AD-5423, a novel anti-psychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties. Oka M, Noda Y, Ochi Y, Furukawa K, Une T, Kurumiya S, Hino K, Karasawa T J PHARMACOL EXP THER 1993 264 158-165
3. Comparative study of 2-(4-ethyl-1-piperazinyl)-4(fluorophenyl)-5,6,7,8,9, 10-hexahydrocycloocta[b]pyridine (AD-5423) and haloperidol for their pharmacological activities related to antipsychotic efficacy and/or adverse side-effects. Noda Y, Kurumiya S, Miura Y, Oka M J PHARMACOL EXP THER 1993 265 745-751
4. AD-5423. Antipsychotic DRUGS FUTURE 1994 19 1 64
5. AD-5423. DRUGS FUTURE 1995 20 1 68
6. Phase I clinical study AD 5423, a new antipsychotic drug with D2 and 5-HT2 antagonist activity. Wakatabe H, Ochiai K, Murasaki M, et al NEUROPSYCHOPHARMACOLOGY 1994 10 3s 117-154
7. Dainippon PHARMA JPN 1995 1465 18
8. Psychopharmacology of atypical neuroleptics. Fujita H, Kanba S, Yagi G JPN J NEUROPSYCHOPHARMACOL 1995 17 9 589-596
9. Recent progress in development of psychotropic drugs (2) - Antipsychotics. Murasaki M JPN J PSYCHOPHARMACOL 1995 15 3 191-210
10. Dainippon outlines pipeline products SCRIP 1995 2086 13
11. Dainippon Pharmaceutical Co Ltd ANNUAL REPORT 1995 January
12. New Drugs in the R&D pipeline...Dainippon PHARMA JPN 1996 1494 21
13. Problematic points of psychotropic drugs. Murasaki M BRAIN NERVE 1995 47 11 1027-1037
14. Dainippon Announces Company Renovation Plan P-UP21 PHARMA JPN 1997 1554 10
15. Dainippon Pharmaceutical Co Ltd ANNUAL REPORT 1996 March 31
16. Schizophrenia - advances in drug therapy. Reynolds GP EXP OPIN INVEST DRUGS 1997 6 7 857-866
17. Determination of a novel anti-psychotic agent AD-5423 and its metabolites in plasma by high-performance liquid chromatography with fluorescence detection. Matsuda M, Sakashita M, Yamaguchi T, Fujii T J PHARM BIOMED ANAL 1997 15 9-10 1449-1456
18. Central serotonin receptor subtypes and drug development. FOLIA PHARMACOL JPN 1997 110 3 97-99
19. Pharmacological profile of AD 5423. Oka M JPN J NEUROPSYCHOPHARMACOL 1995 17 10 729-736
20. AD-5423 DRUGS FUTURE 1996 21 1 72
21. AD-5423 DRUGS FUTURE 1997 22 1 62
22. Fifth North American ISSX Meeting Yamaguchii T, Sakahita H, Furukawa H, et al ISSX PROC 1993 4 68
23. Novel potential antipsychotics: 4-Phenyl-2-(1-piperazinyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridines. Hino K, Kai K, Sakomoto M, Murata T, Oka M, Matsumoto J ACS 1990 MEDI 11
24. Study on the optimum use of the antipsychotic drug AD-54423 in tablet formulation. Yamammura N, Tan K, Fujiokatt, Nakamura Y ARCH PRACT PHARM 1994 Suppl Abs B-15
25. YAMAICHI STOCKBROKERS REP. 1996. 12 February.